submit to the journals

Emerging Role of Safinamide in Parkinson’s Disease Therapy

European Neurological Review, 2014;9(2):108-112 DOI: http://doi.org/10.17925/ENR.2014.09.02.108

Abstract:

Parkinson’s disease is associated with motor complications, especially dyskinesias, which limit dopaminergic replacement therapy. Safinamide is a water-soluble, orally active α-aminoamide derivative that modulates dopaminergic and glutamatergic neurotransmission with a unique dual mechanism of action. It improves motor symptoms, motor complications, quality of life and ‘on’ and ‘off’ time even in combination with other Parkinson’s disease (PD) medications, such as dopamine agonists and levodopa (LD). Safinamide reduces ‘off’ time and extends ‘on’ time without troublesome dyskinesia. Furthermore, safinamide maintains its effects after long-term treatment and has a favourable pharmacokinetic and side-effect profile. It therefore has the potential to become an important drug in PD management. This review will summarise data from animals, healthy human subjects and patients with PD on the long-term efficacy and safety of safinamide.

Keywords: Add-on therapy, dyskinesia, dopaminergic, monoamine oxidase b, non-dopaminergic, Parkinson’s disease, safinamide
Disclosure: Dr. Kulisevsky has received honoraria for lecturing or advisory boards from Teva, UCB, Zambon, Lundbeck and Abbvie, and reserach support from Instituto de Salud Carlos III, Spain.
Acknowledgments: Editorial assistance was provided by Catherine Amey, PhD, at Touch Medical Media.
Received: August 01, 2014 Accepted: August 22, 2014
Correspondence: Jaime Kulisevsky, Sant Pau Hospital. Sant Antoni M. Claret 167; 08025 Barcelona, Spain. E: jkulisevsky@santpau.cat
Support: The publication of this article was supported by Zambon SpA. The views and opinions expressed are those of the author and do not necessarily reflect those of Zambon SpA.

Parkinson’s disease (PD) is a neurodegenerative disorder characterised by the loss of dopaminergic neurons in the substantia nigra pars compacta – non-dopaminergic neurotransmission is also involved. In the basal ganglia circuitry there are many non-dopaminergic neurotransmitters and neuromodulators involved in the control of motor symptoms and implicated in the development of motor complications following long-term levodopa (LD) therapy.1–4 Indeed, PD is no longer seen purely as a disease of the dopaminergic system.5 In particular, overactive glutamate transmission plays a role in the progression of PD.6–8 Targeting non-dopaminergic systems is thus a complementary approach to improve and control such motor complications, removing the need for further increases in LD, which may otherwise worsen motor fluctuations.4

Safinamide (see Figure 1) is an oral, once-a-day adjunctive therapy developed for any stage of PD. Safinamide is a unique molecule with novel mechanisms of action (dopaminergic and non-dopaminergic) that include monoamine oxidase-B (MAO-B) inhibition, sodium channel blockade and calcium channel modulation, thus inhibiting the excessive glutamate release. The sodium channel inhibition is concentration- and state-dependent, and does not influence physiological activity, avoiding depressant effects on the central nervous system (CNS). Safinamide does not affect L-type calcium channels (no effects in blood pressure and heart rate).9–12

Safinamide is more selective for MAO-B versus MAO-A than selegiline and rasagiline: 1,000-fold in humans, compared with 127-fold for selegiline and 103-fold for rasagiline.10,13–15 This higher selectivity is related to the absence of diet restrictions pertaining to the clinical use of the drug. Moreover, the MAO-B inhibition is totally reversible, allowing better clinical manageability and limiting possible drug–drug interactions.10,14,15

In animal models, safinamide has been shown to reduce LD-induced dyskinesias.10,16 It may also have neuroprotective effects.8 Safinamide inhibits α-1 receptors in the endoplasmic reticulum.17 These receptors are believed to be multifunctional regulatory proteins with a role in CNS development, plasticity and neurodegeneration. Safinamide has been shown to completely prevent forebrain dopamine depletion and neuronal cell death in the gerbil substantia nigra when administered prior to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.18 In animal epilepsy models, safinamide was shown to counteract neuronal death that had been induced by excitotoxin.19 Possible mechanisms of action for safinamide’s potential neuroprotective properties are MAO-B inhibition20 and reduction in glutamate release.10,11

The efficacy and safety of safinamide has been evaluated in clinical studies as add-on therapy to dopamine agonists (DA) in early-stage PD21–23 and as add-on to LD (with possibly other anti-Parkinson’s drugs) in mid- to late-stage PD.24–26

Evidence from Healthy Volunteers
Four clinical trials in male, healthy volunteers, which included a food interaction trial, covering doses from 25 µg/kg to 10 mg/kg were carried out to investigate the pharmacokinetics, pharmacodynamics and tolerability of safinamide, administered in single or repeated doses to steady state.27 The trials showed that near complete inhibition of MAO-B is achieved with a safinamide dose of 0.3 mg/kg and that enteral absorption of the drug is linear and proportional to the doses administered. The drug is cleared from the body with a half-life (t1/2) approximately equal to 22 h, without producing any clinically relevant accumulation at steady state. No evident MAO-A inhibition was observed at doses up to 10 mg/kg.

In an investigation of the absorption, disposition, elimination and metabolic pathways, a single oral dose of 400 mg 14C-safinamide (as methanesulphonate salt), uniformly labelled in metabolically stable positions, was administered to healthy volunteers.28 Six male, non-smoking healthy male volunteers were included. Maximum concentration was achieved at 1 h (plasma, median Tmax) for parent drug and at 7 and 1.5 h for plasma and whole blood 14C radioactivity, respectively. Terminal t1/2 was about 22 h for unchanged safinamide. By contrast, 14C radioactivity decreased in a biphasic manner with a terminal t1/2 of 80 h. The differences in t1/2 observed between parent safinamide and 14C radioactivity in plasma can be explained by the presence of a varying mixture of metabolites that are cleared from the body compartments at different rates. Safinamide deaminated acid and the N-dealkylated acid were identified as major metabolites in urine and plasma. These results indicated that safinamide can be administered as a single daily dose.

Nonselective MAO inhibitors or MAO A inhibitors can lead to a life-threatening hypertensive crisis through the potentiation of peripheral adrenergic stimulation caused by tyramine ingested with food such as seasoned cheese or chicken liver, i.e. the ‘cheese effect’.29 To assess the risk of inducing this cheese effect, the effect of safinamide on the pressor response to tyramine was compared with placebo in healthy male volunteers.30 The amount of tyramine needed to reach a blood pressure increase was the same after safinamide 2 mg/kg oral load versus placebo, suggesting that dietary restrictions for food high in tyramine should not be necessary with safinamide treatment. Furthermore, in healthy volunteers safinamide 300 mg administered o.d. under fasting conditions did not change the tyramine pressor response at steady state after 6–7 days of treatment.31

References:
  1. Graybiel AM, Neurotransmitters and neuromodulators in the basal ganglia, Trends Neurosci, 1990;13,244–54.
  2. Albin RL, Young AB, Penney JB, The functional anatomy of disorders of the basal ganglia, Trends Neurosci, 1995;18:63–4.
  3. Braak H, Del Tredici K, Rub U, et al., Staging of brain pathology related to sporadic Parkinson’s disease, Neurobiol Aging, 2003;24:197–211.
  4. Fox SH, Non-dopaminergic treatments for motor control in Parkinson’s disease, Drugs, 2013;73:1405–15.
  5. Huot P, Fox SH, Nondopaminergic treatments for Parkinson’s disease, Neurodegener Dis Manag, 2011;1:491–512.
  6. Blandini F, Porter RH, Greenamyre JT, Glutamate and Parkinson’s disease, Mol Neurobiol, 1996;12:73–94.
  7. Chase TN, Bibbiani F, Oh JD, Striatal glutamatergic mechanisms and extrapyramidal movement disorders, Neurotox Res, 2003;5:139–46.
  8. Borgohain R, Kandadai RM, Safinamide: a novel anti- Parkinsonian drug with multiple actions, Neurodegen Dis Manage 2013;3:231–40.
  9. Pevarello P, Bonsignori A, Dostert P, et al., Synthesis and anticonvulsant activity of a new class of 2-[(arylalkyl) amino] alkanamide derivatives, J Med Chem, 1998;41:579–90.
  10. Caccia C, Maj R, Calabresi M, et al., Safinamide: from molecular targets to a new anti-Parkinson drug, Neurology, 2006;67(7 Suppl. 2):S18–23.
  11. Caccia C, Salvati P, Rossetti S, Anand R, Safinamide: Modulation of dopaminergic and glutamatergic system, Mov Disord, 2008;67:S22–3.
  12. Chazot PL, Safinamide for the treatment of Parkinson’s disease, epilepsy and restless legs syndrome, Curr Opin Investig Drugs, 2007;8:570–9.
  13. Binda C, Wang J, Pisani L, et al., Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs, J Med Chem, 2007;50:5848–52.
  14. Onofrj M, Bonanni L, Thomas A, An expert opinion on safinamide in Parkinson’s disease, Expert Opin Investig Drugs, 2008;17:1115–25.
  15. Müller T, Current status of safinamide for the drug portfolio of Parkinson’s disease therapy, Expert Rev Neurother, 2013;13:969–77.
  16. Grégoire L, Jourdain VA, Townsend M, et al., Safinamide reduces dyskinesias and prolongs l-DOPA antiparkinsonian effect in parkinsonian monkeys, Parkinsonism Relat Disord, 2013;19:508–14.
  17. Fariello RG, McArthur RA, Bonsignori A, et al., Preclinical evaluation of PNU-151774E as a novel anticonvulsant, J Pharmacol Exp Ther, 1998;285:397–403.
  18. Vaghi F, Maj R, Rosa B, et al., Neuroprotective effect of PNU- 151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils, Soc Neurosci Abstr, 1997;23:545.
  19. Maj R, Fariello RG, Ukmar G, et al., PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat, Eur J Pharmacol, 1998;359:27–32.
  20. Kupsch A, Sautter J, Götz ME, et al., Monoamine oxidaseinhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline, J Neural Transm, 2001;108:985–1009.
  21. Stocchi F, Borgohain R, Onofrj M, et al., A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson’s disease patients, Mov Disord, 2012;27:106–12.
  22. Schapira AH, Stocchi F, Borgohain R, et al., Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson’s disease, Eur J Neurol, 2013;20:271–80.
  23. Anand R, Barone P, Fox S, et al., Safinamide is effective as add-on treatment in both early and advanced PD. Presented at the XXI World Congress of Neurology, Wien, Austria, 21–26 September 2013.
  24. Schapira AH, Fox S, Hauser, et al., Safinamide significantly improves responder rates in fluctuating PD patients as add-on to levodopa (SETTLE). Presented at the 17th International Congress of Parkinson’s Disease and Movement Disorders, Sydney, Australia, 16–20 June 2013.
  25. Borgohain R, Szasz J, Stanzione P, et al., Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations, Mov Disord, 2014;29:229–37.
  26. Borgohain R, Szasz J, Stanzione P, et al., Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late PD, Mov Disord, 2014;29:1273–80.
  27. Marzo A, Dal Bo L, Monti NC, et al., Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity, Pharmacol Res, 2004;50:77–85.
  28. Leuratti C, Sardina M, Ventura P, et al., Disposition and metabolism of safinamide, a novel drug for Parkinson’s disease, in healthy male volunteers, Pharmacology, 2013;92:207–16.
  29. Walker SE, Shulman KI, Tailor SA, Gardner D, Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets, J Clin Psychopharmacol, 1996;16:383–8.
  30. Cattaneo C, Caccia C, Marzo A, et al., Pressor response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective, reversible monoamine oxidase B inhibition, Clin Neuropharmacol, 2003;26:213–7.
  31. Di Stefano AF, Rusca A, Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers, Naunyn Schmiedebergs Arch Pharmacol, 2011;384:505–15.
  32. Stocchi F, Arnold G, Onofrj M, et al., Improvement of motor function in early Parkinson disease by safinamide, Neurology, 2004;63:746–8.
  33. Goetz CG, Stebbins GT, Shale HM, et al., Utility of an objective dyskinesia rating scale for Parkinson’s disease: inter- and intrarater reliability assessment, Mov Disord, 1994;9:390–4.
  34. Kalász H, Magyar K, Szke É, et al., Metabolism of selegiline [(-)-deprenyl)], Curr Med Chem, 2014;21(13):1522–30.
Keywords: Add-on therapy, dyskinesia, dopaminergic, monoamine oxidase b, non-dopaminergic, Parkinson’s disease, safinamide